insightskies

  Radiopharmaceuticals in Nuclear Medicine Market Radiopharmaceuticals in nuclear medicine are radioactive drugs that emit radiation used for diagnostic imaging and therapeutic purposes. Some of the commonly used radiopharmaceuticals include Tc-99m, F-18, I-123/I-131, and Ga-67. They play a vital role in nuclear medicine procedures like positron emission tomography (PET), single-photon emission computed tomography (SPECT), and therapeutic radiopharmaceuticals. The increasing prevalence of chronic diseases like cancer, heart diseases is driving the demand for effective diagnostic and therapeutic procedures. The global radiopharmaceuticals in nuclear medicine market is estimated to be valued at US$ 9115.96 Mn in 2024 and is expected to exhibit a CAGR of 8.0% over the forecast period 2024 to 2031. Key Takeaways Key players: Key players operating in the radiopharmaceuticals in nuclear medicine market are Progenics Pharmaceuticals, Inc., NorthStar Medical Radioisotopes LLC, Curium Pharma

  Non-Small Cell Lung Cancer Treatment Market  Non-small cell lung cancer (NSCLC) refers to a type of lung cancer that is the most common type, accounting for about 85% of all lung cancers. Most NSCLC are associated with smoking tobacco. Treatments for NSCLC include surgery, chemotherapy, radiation therapy, targeted drug therapy, and immunotherapy. Targeted drug therapies have revolutionized treatment for some types of NSCLC by blocking the growth and spread of cancer cells. The global non-small cell lung cancer treatment market is estimated to be valued at US$ 26.10 Bn in 2024 and is expected to exhibit a CAGR of 9.4% over the forecast period from 2024 to 2031. Key Takeaways Key players operating in the non-small cell lung cancer treatment market are AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Eli Lilly and Company, Merck & Co., Inc., Otsuka Pharmaceutical Company, Ltd., Sanofi, and The Medicines Company. Key players are focu

  The healthcare revenue cycle management market has witnessed significant growth over the past few years, driven by the growing need to manage revenue loss and optimize insurance claim processes. Revenue cycle management solutions help healthcare providers optimize billing and coding activities, thereby improving revenue collections. The software offers charge capture, claims processing and payment posting. It also provides key tools for analyzing denied claims to initiate corrective actions. Additionally, revenue cycle management systems offer claims quality control, accounts receivable management and electronic remittance posting required for efficient revenue management. The Global Healthcare Revenue Cycle Management Market is estimated to be valued at US$ 63.49 Mn in 2024 and is expected to exhibit a CAGR of 5.6% over the forecast period 2024 To 2031. Key Takeaways Key players operating in the Healthcare Revenue Cycle Management market are Life Extension, Pure Encapsulations, Nu

  Disposable Medical Gloves Market  The disposable medical gloves market has seen significant growth in recent years. Disposable medical gloves are essential for healthcare professionals to avoid cross-contamination between patients and to maintain sterility while treating patients or handling samples and medical equipment. Made of synthetic materials like nitrile, vinyl or latex, these gloves provide a protective barrier and are integral to standard infection control protocols. The rising incidences of Hospital Associated Infections (HAIs) and growing awareness surrounding hygiene and individual healthcare has propelled the demand for disposable gloves globally. The Global disposable medical gloves market is estimated to be valued at US$ 8.51 Bn in 2024 and is expected to exhibit a CAGR of 9.5% over the forecast period 2024 to 2031. Key Takeaways Key players operating in the disposable medical gloves market are Cardinal Health, Inc., Adventa Berhad, Ansell Ltd., Dynarex Corporation

  Cryoablation Devices Market The cryoablation devices market is engaged in manufacturing systems and probes involved in cryoablation or cryotherapy procedures. Cryoablation is a minimally invasive procedure that uses extreme cold instead of heat to “ablate” or destroy tissue. Liquid nitrogen or argon is circulated through probes placed inside or against the target tissue to freeze it. The freezing destroys the cellular structure and when the cells awaken the result is cell death. The technique is commonly used to treat some cancers and cardiac arrhythmias. Cryosurgery or cryotherapy offers more targeted freezing compared with earlier procedures and causes less damage to nearby tissue. The Global cryoablation devices market is estimated to be valued at US$ 408.1 Mn in 2024 and is expected to exhibit a CAGR of 14% over the forecast period 2024 To 2031. Key Takeaways Key players operating in the cryoablation devices market are Geneva Bioinformatics (Genebio), Dassault Systems, Eurof

  Cosmeceuticals Market Cosmeceuticals refer to cosmetic products that are infused with biologically active ingredients that can improve the health and appearance of the skin. They provide anti-ageing, anti-acne, anti-inflammatory, and skin-lightening benefits. The rising consumer health and beauty consciousness has boosted the demand for cosmeceuticals. The multi-functional attributes of cosmeceuticals that provide skincare and make-up benefits in a single product have further augmented their popularity. The global cosmeceutical   market was valued at  US$ 76,875.0 Mn  in 2022 and is forecast to reach a value of  US$ 153,318.7 Mn  by  2030  at a  CAGR of 9.02%  between  2023 and 2030 .  Key Takeaways Key players operating in the Cosmeceuticals market are Bayer AG, Henkel AG and Co. KgaA, Avon Products Inc., Johnson and Johnson Inc., Kao Corporation, Beiersdorf AG, Groupe Clarins SA, Revlon Inc., Shiseido Co. Ltd., Unilever PLC, Procter and Gamble, L'Or;al SA, Lotus Herbals Pvt

  Clinical Trial Management System Market The Clinical Trial Management System (CTMS) is a software system used by biotechnology and pharmaceutical industries to manage clinical trials. It allows the management of planning, preparation and execution of trials by supporting processes such as trial design, support & supplies, safety reporting, medical coding and validation. CTMS provides several advantages like increased efficiency through automation, real-time access to data, improved compliance and reporting. There is a growing need for CTMS among organizations conducting clinical research to streamline complex trial processes and meet regulatory requirements. The global clinical trial management system market is estimated to be valued at US$ 2.10 Bn in 2024 and is expected to exhibit a CAGR of 14.9% over the forecast period 2024 to 2031. Key Takeaways Key players operating in the Clinical Trial Management System are Menarini Group, N-Finders Co. Ltd., 1st SurgiConcept, River Aes

  Bone Marrow Transplant Market  The bone marrow transplant market provides life-saving treatment for patients suffering from various types of cancer, blood disorders, and immune deficiencies. Bone marrow transplantation is a procedure where unhealthy bone marrow is destroyed using chemotherapy or radiation therapy and is then replaced by healthy bone marrow stem cells. It aids in restoring the body's ability to produce red blood cells, white blood cells, and platelets. The demand for bone marrow transplantation is rising owing to the increasing prevalence of various types of cancers such as leukemia, lymphoma, and other hematologic malignancies. The Global Bone Marrow Transplant Market is estimated to be valued at US$ 10.72 Bn in 2024 and is expected to exhibit a CAGR of 4.3% over the forecast period 2024 To 2031. Key Takeaways Key players operating in the bone marrow transplant market are Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Getinge AB, General Electric Company,

Antibody Drug Conjugates Market The Antibody Drug Conjugates Market involves antibodies that are attached or conjugated to biologically active drugs or drug warheads through chemical linkers. ADCs function by selectively delivering cytotoxic, or cell-killing, agents to tumors while minimizing toxicity to normal tissues. This targeted approach is known to increase efficacy without exacerbating toxicity. The global antibody drug conjugates market is estimated to be valued at US$ 7.02 Bn in 2024 and is expected to exhibit a CAGR of 14.2% over the forecast period 2024 to 2031. Key Takeaways Key players operating in the Antibody Drug Conjugates market are AstraZeneca PLC, Daiichi Sankyo Company, Limited, Novasep, ADC Therapeutics SA, Alentis Therapeutics AG, F. Hoffmann-La Roche, Gilead Sciences, Inc., AbbVie Inc., Biosion USA, Inc., Astellas Pharma Inc., Duality Biologics (Suzhou) Co. Ltd., BioNTech SE, LaNova Medicines Ltd., Bliss Biopharmaceutical, Eisai Co., Ltd., ProfoundBio, Pfizer,